Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B1 | P15121 | 2/20 | 0.45 |
| ▸ | CES2 | O00748 | 1/20 | 0.44 |
| ▸ | CES1 | P23141 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | ACKR3 | P25106 | 2/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | ALPL | P05186 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5796374 | 0.86 | AKR1B1 (0.46) | AKR1B1KMT2AMEN1RAB9ANPC1 | |
| SCHEMBL4245618 | 0.80 | RAB9A (0.51) | AKR1B1CES2CES1KMT2AMEN1 | |
| SCHEMBL3126547 | 0.73 | CES2 (0.45) | CES2CES1HTTRAB9ANPC1 | |
| SCHEMBL5799397 | 0.73 | PIM1 (0.45) | KMT2AMEN1RAB9ANPC1HTR2A | |
| SCHEMBL76004 | 0.71 | CES2 (0.46) | CES2CES1KMT2AMEN1RAB9A | |
| SCHEMBL11015620 | 0.71 | CES2 (0.42) | CES2CES1KMT2AHTTRAB9A | |
| SCHEMBL7269432 | 0.70 | IDO1 (0.46) | CES2CES1KMT2ARAB9AACKR3 | |
| SCHEMBL7274242 | 0.70 | CES2 (0.45) | CES2CES1HTTRAB9ACYP1A2 | |
| SCHEMBL4242626 | 0.70 | CES2 (0.43) | AKR1B1CES2CES1KMT2AHTT | |
| SCHEMBL434429 | 0.70 | LMNA (0.42) | AKR1B1KMT2AHTTMEN1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090042856-A1 | PYRIDAZINONE DERIVATIVES USED FOR THE TREATMENT OF PAIN | ASTELLAS PHARMA INC (JP) | 2009-02-12 | — | — | US | disclosed |
| EP-1919919-A1 | PYRIDAZINONE DERIVATIVES USED FOR THE TREATMENT OF PAIN | Astellas Pharma Inc. (JP) | 2008-05-14 | — | — | EP | disclosed |
| WO-2007026950-A1 | PYRIDAZINONE DERIVATIVES USED FOR THE TREATMENT OF PAIN | ASTELLAS PHARMA INC. (JP) | 2007-03-08 | — | — | WO | disclosed |
| WO-2006038734-A1 | PYRIDAZINONE DERIVATIVES CYTOKINES INHIBITORS | ASTELLAS PHARMA INC. (JP) | 2006-04-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042856-A1 | PYRIDAZINONE DERIVATIVES USED FOR THE TREATMENT OF PAIN | HRH2, OPRD1, HRH4 | AKR1B1 1120/4885CES2 4158/4885CES1 3853/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.